IN2015DN01163A - - Google Patents

Info

Publication number
IN2015DN01163A
IN2015DN01163A IN1163DEN2015A IN2015DN01163A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A IN 1163DEN2015 A IN1163DEN2015 A IN 1163DEN2015A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A
Authority
IN
India
Prior art keywords
syndrome
mediated
disorder
transportation
disease
Prior art date
Application number
Other languages
English (en)
Inventor
Jan Jiricek
Ravinder Reddy Kondreddi
Paul William Smith
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN01163A publication Critical patent/IN2015DN01163A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1163DEN2015 2012-09-07 2015-02-12 IN2015DN01163A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261698033P 2012-09-07 2012-09-07
PCT/IB2013/058318 WO2014037900A1 (en) 2012-09-07 2013-09-05 Indole carboxamide derivatives and uses thereof

Publications (1)

Publication Number Publication Date
IN2015DN01163A true IN2015DN01163A (enExample) 2015-06-26

Family

ID=49585451

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1163DEN2015 IN2015DN01163A (enExample) 2012-09-07 2015-02-12

Country Status (11)

Country Link
US (3) US9447039B2 (enExample)
EP (1) EP2892880B1 (enExample)
JP (1) JP6223452B2 (enExample)
KR (1) KR20150048759A (enExample)
CN (1) CN104603106B (enExample)
BR (1) BR112015004666B1 (enExample)
CA (1) CA2881351A1 (enExample)
EA (1) EA028093B1 (enExample)
ES (1) ES2660210T3 (enExample)
IN (1) IN2015DN01163A (enExample)
WO (1) WO2014037900A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715417B (zh) * 2014-04-04 2020-01-14 爱欧梅特制药公司 药物中使用的吲哚衍生物
WO2015164482A1 (en) * 2014-04-22 2015-10-29 The Johns Hopkins University Inhibitors of drug-resistant mycobacterium tuberculosis
EA032277B1 (ru) * 2014-10-24 2019-05-31 Бристол-Майерс Сквибб Компани Индолкарбоксамидные соединения
WO2017177979A1 (zh) * 2016-04-15 2017-10-19 中国科学院上海有机化学研究所 杂环羧酸酰胺配体及其在铜催化芳基卤代物偶联反应中的用途
CN106085868B (zh) * 2016-06-15 2019-07-12 中国医学科学院医药生物技术研究所 一株曲霉菌及其应用
US10383848B2 (en) * 2016-08-04 2019-08-20 Creighton University Indole-based therapeutics
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
US11180459B2 (en) 2017-03-10 2021-11-23 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
AU2018231120B2 (en) 2017-03-10 2022-06-23 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
WO2018165614A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3630109A4 (en) * 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey BACTERIAL EFFLUX PUMP INHIBITORS
WO2019005841A1 (en) * 2017-06-26 2019-01-03 Rutgers, The State University Of New Jersey THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
US11718633B2 (en) 2018-05-17 2023-08-08 Council Of Scientific And Industrial Research Indole compounds, process for the preparation and use thereof
KR102219563B1 (ko) * 2019-02-15 2021-02-24 에스티팜 주식회사 페나진 유도체 제조를 위한 중간체 및 그의 제조방법
EP4034103A4 (en) * 2019-09-26 2023-10-25 The Global Alliance for TB Drug Development, Inc. Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
KR20220070491A (ko) * 2019-09-26 2022-05-31 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 미코박테리아 감염의 치료를 위한 아자인돌 카복사미드 화합물
CN110577483B (zh) * 2019-09-26 2020-05-12 海南医学院 一种3,3-二取代-2-吲哚酮的绿色合成方法
BR112022005728A2 (pt) * 2019-09-26 2022-08-23 Global Alliance For Tb Drug Development Inc Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas
RU2767542C1 (ru) * 2021-05-24 2022-03-17 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов
CN115583908B (zh) * 2021-07-05 2024-08-06 西北农林科技大学 一种吲哚甲酰胺类化合物及其制备方法和用途
US12012398B2 (en) * 2021-07-12 2024-06-18 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
IL321166A (en) * 2022-12-02 2025-07-01 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
CN118724763B (zh) * 2024-09-02 2024-12-06 辽宁龙田化工科技有限公司 一种4-甲基苯磺酰氯合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US883049A (en) * 1907-09-12 1908-03-24 John W Piver Tongue-and-groove joint for flooring.
FR2705095B1 (fr) * 1993-05-12 1995-06-23 Adir Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US7129225B2 (en) 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
US6759428B2 (en) 2001-12-04 2004-07-06 Roche Palo Alto Llc Indole nitriles
CA2467435A1 (en) 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
JPWO2003091213A1 (ja) * 2002-04-25 2005-09-02 アステラス製薬株式会社 新規なアミド誘導体又はその塩
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0428173D0 (en) * 2004-12-23 2005-01-26 Astrazeneca Ab Compounds
US8691859B2 (en) * 2005-08-12 2014-04-08 The United States Of America As Represented By The Secretary Of The Army Broad spectrum antibacterial compounds
CN101460497A (zh) 2006-04-04 2009-06-17 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2009063495A2 (en) 2007-09-20 2009-05-22 Cadila Healthcare Limited Substituted indole and its derivatives as cannabinoid modulators
MX2011006171A (es) * 2008-12-19 2011-06-20 Squibb Bristol Myers Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
AP3069A (en) 2009-02-27 2014-12-31 Siga Technologies Inc Thienopyridine derivatives for the treatment and prvention of dengue virus infection
EP2459562A1 (en) 2009-07-31 2012-06-06 Biocryst Pharmaceuticals, Inc. Pyrrolo [1, 2-b]pyridazine derivatives as janus kinase inhibitors
JP5848712B2 (ja) 2009-12-11 2016-01-27 ノノ インコーポレイテッド 虚血性疾患および他の疾患を治療するための薬剤および方法
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof

Also Published As

Publication number Publication date
US9447039B2 (en) 2016-09-20
EA028093B1 (ru) 2017-10-31
EA201590504A1 (ru) 2015-07-30
CN104603106A (zh) 2015-05-06
JP2015527388A (ja) 2015-09-17
KR20150048759A (ko) 2015-05-07
AU2013311235A1 (en) 2015-02-26
CN104603106B (zh) 2017-05-10
AU2013311235B2 (en) 2016-03-24
CA2881351A1 (en) 2014-03-13
WO2014037900A1 (en) 2014-03-13
ES2660210T3 (es) 2018-03-21
JP6223452B2 (ja) 2017-11-01
EP2892880A1 (en) 2015-07-15
EP2892880B1 (en) 2017-11-22
BR112015004666B1 (pt) 2022-04-26
BR112015004666A2 (pt) 2017-07-04
US20160355477A1 (en) 2016-12-08
US20210032202A1 (en) 2021-02-04
US20150175539A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
IN2015DN01163A (enExample)
EA201591527A1 (ru) Новые производные пиридина
PH12015501083A1 (en) Novel pyridine derivatives
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
MX350539B (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
EA201291317A1 (ru) Тетрагидропиридопиримидиновые производные
PH12015501933B1 (en) Novel pyridine derivatives
PH12015501843A1 (en) Novel pyrazol derivatives
MX2014004920A (es) Nuevos derivados de pirazina.
MY178390A (en) Inhibitors of iap
MY180050A (en) Novel purine derivatives
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX363458B (es) Nuevos derivados de tetrazolona.
PH12015500262A1 (en) Novel pyridine derivatives
MX351093B (es) Nuevos derivados de azetidina.
IN2015DN02513A (enExample)
MX2016004333A (es) Uso de odiparcil en el tratamiento de una mucopolisacaridosis.